Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. Allegations - The lawsuit claims that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness, overstating its clinical, regulatory, and commercial prospects [2]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than represented, leading to an overestimation of Alto's business and financial prospects [2]. Stock Performance - Following the announcement on October 22, 2024, that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4].

Morris Kandinov LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. common stock pursuant and/or traceable to the offering documents issued in connection with the company's initial public offering conducted on or about February 2, 2024, and/or (b) Alto securities between February 2, 2024 and October 22, 2024. Alto operates as a clinical- stage biopharmaceutical company in the U.S. The Company's product pipeline include ...

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) The Company's product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto's business and/or financial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleadi ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of common stock of Alto Neuroscience, Inc. due to alleged misleading statements regarding the company's business and product effectiveness during the Class Period from February 2, 2024, to October 22, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Alto made materially false and misleading statements about its product ALTO-100, particularly regarding its effectiveness in treating major depressive disorder, which led to overstated clinical and commercial prospects [5]. - Investors are encouraged to join the class action lawsuit, with the deadline to serve as lead plaintiff set for September 19, 2025 [1][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable settlement against a Chinese company and securing over $438 million for investors in 2019 alone [4].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the company's product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [5].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to t ...

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) due to allegations of misleading statements regarding the effectiveness of its product pipeline, ALTO-100 [1][2]. Group 1: Allegations - The lawsuit claims that during the class period, the defendants made materially false and misleading statements about ALTO-100's effectiveness in treating major depressive disorder [2]. - It is alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to inflated business and financial prospects for Alto Neuroscience [2]. - Consequently, the company's public statements were deemed materially false and misleading throughout the relevant time frame [2]. Group 2: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [1]. - Shareholders are encouraged to register for the class action by September 19, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired: (a) Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the "IPO" or "Offering"); and/or (b) Alto securities between February 2, ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Alto Neuroscience, Inc. common stock, alleging that the company made materially false and misleading statements regarding its business and prospects during the Class Period from February 2, 2024, to October 22, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Alto's offering documents contained false statements about the effectiveness of ALTO-100 in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by September 19, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].